Delivery Order SPE2DB24D2013-SPE2DB24FCHHJ

Award Date 8/1/24
Potential Completion Date 8/2/24
Potential Value $32K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a $17,804.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of 4565295301 - RINVOQ ER 30 MG TABLET UU 30S. This order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 through December 2025, which allows DLA Troop Support Medical to efficiently procure a comprehensive range of pharmaceutical and medical supplies to support military treatment programs and facilities worldwide....
The U.S. Department of Defense (DOD) Defense Logistics Agency (DLA) awarded a $14,048.42 firm fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the provision of 4566803438 - RINVOQ ER 15 MG TABLET UU 30S. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a comprehensive vehicle for supplying a range of pharmaceutical...
The Defense Logistics Agency (DLA) awarded a $69,691.00 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp Corporate Office Division, a major pharmaceutical distributor, for the supply of RINVOQ ER 45 MG TABLET UU 28S. This is a delivery order issued under an existing Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, which has a ceiling value of up to $999,999,999 through December 2025 for the provision of a comprehensive range...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for $18,046.26 to provide RINVOQ ER 30 MG TABLET UU 30S. This order is part of an indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract vehicle for Amerisourcebergen to deliver...
The U.S. Defense Logistics Agency (DLA) awarded a $26,515.61 firm-fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 30 MG TABLET UU 30S. This order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 with DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical and medical supplies to military treatment facilities worldwide. The contract does not have a set-aside designation. AmerisourceBergen, a major...
The U.S. Defense Logistics Agency (DLA) awarded a $40,807.49 firm fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide RINVOQ ER 45 MG TABLET UU 28S. This contract has an ultimate completion date of March 14, 2025 and was not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as a primary vehicle for providing a comprehensive range of...
This is a $14,547.42 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation's Corporate Office division. The contract is for the supply of RINVOQ ER 30 MG TABLET, a prescription pharmaceutical product, with an ultimate completion date of August 21, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical for delivering a...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 45 MG TABLET for a ceiling value of $48,405.36. The contract has an ultimate completion date of October 10, 2024 and is a firm fixed-price contract. AmerisourceBergen Drug Corp is a major pharmaceutical distributor that has been awarded numerous contracts by federal agencies, including the DLA and the Department of Justice Federal Bureau of Investigation, to...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $10,640.94 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of RINVOQ ER 15 MG TABLET, a specialty medication, to support government healthcare programs. This award is part of AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999 through December 2025, for providing a wide range of...
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of RINVOQ ER 30 MG TABLET UU 30S. The contract has a ceiling value of $38,667.19 and a period of performance ending on July 16, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
  • SPE2DB24D2013
    Indefinite Delivery Contract
  • SPE2DB24D2013-SPE2DB24FCHHJ
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a $31,704.61 firm-fixed price delivery order to AmerisourceBergen Drug Corp's Corporate Office Division to supply RINVOQ ER 45 MG TABLET UU 28S pharmaceutical products. This order was placed under a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 through December 2025, which enables DLA Troop Support Medical to efficiently procure a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract has no set-aside designation and is expected to be completed by August 2, 2024.

Generated 10/31/24, 10:43 AM